Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data

CALGARY, Canada - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of the Company’s Phase 1b/2a clinical trial for RVX-208, an oral small molecule in development to treat atherosclerosis and cardiovascular disease.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix’s website and can be accessed from the following address services.choruscall.com/links/resverlogix090928.html.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer’s disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email: Theresa@resverlogix.com; US Investor Relations: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1-212+966-3650, Email: susan@sanoonan.com; US Media Relations: Eric Goldman, Vice President, Rx Communications Group, Phone: +1-917-322-2563, Email: egoldman@rxir.com

Source: Resverlogix Corp.

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email:
Theresa at resverlogix.com; US Investor Relations: Susan Noonan, Managing
Partner, S.A. Noonan Communications, LLC, Phone: +1-212+966-3650, Email:
susan at sanoonan.com; US Media Relations: Eric Goldman, Vice President, Rx
Communications Group, Phone: +1-917-322-2563, Email: egoldman at rxir.com